Edwards Lifesciences posted strong Q2 results with sales rising 11.9% to $1.53 billion, beating Wall Street expectations. While net earnings dipped 7.7%, adjusted EPS hit 67¢—5¢ above consensus.
TAVR revenue reached $1.1 billion (up 8.9%), while transcatheter mitral and tricuspid therapies soared 61.9% to $134.5 million. Following the strong quarter, Edwards raised its full-year sales growth guidance to 9–10% and EPS to the upper end of $2.40–$2.50.
CEO Bernard Zovighian cited momentum across the company’s aortic, mitral, and tricuspid portfolios, with analysts expecting continued tailwinds from new FDA approvals and market exits by competitors.
Follow MEDWIRE.AI for the latest in cardiovascular medtech earnings.
